Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor
Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell–based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the e...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IOS Press
2017-03-01
|
Series: | Tumor Biology |
Online Access: | https://doi.org/10.1177/1010428317695021 |
id |
doaj-9f5cdbd2eb484972bdf87519dc7eea8c |
---|---|
record_format |
Article |
spelling |
doaj-9f5cdbd2eb484972bdf87519dc7eea8c2021-05-02T21:34:26ZengIOS PressTumor Biology1423-03802017-03-013910.1177/1010428317695021Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitorSamaneh Arab0Nasim Kheshtchin1Maryam Ajami2Mahbubeh Ashurpoor3Aida Safvati4Afshin Namdar5Reza Mirzaei6Neda Mousavi Niri7Farhad Jadidi-Niaragh8Mohammad Hossein Ghahremani9Jamshid Hadjati10Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Immunology, Tarbiat Modares University, Tehran, IranDepartment of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Biotechnology, Faculty of Advanced Medical Sciences, Tehran Medical Branch, Islamic Azad University, Tehran, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, IranDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, IranDendritic cells are important in initiating immune responses; therefore, a range of dendritic cell–based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell–based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell–based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell–based cancer immunotherapy.https://doi.org/10.1177/1010428317695021 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Samaneh Arab Nasim Kheshtchin Maryam Ajami Mahbubeh Ashurpoor Aida Safvati Afshin Namdar Reza Mirzaei Neda Mousavi Niri Farhad Jadidi-Niaragh Mohammad Hossein Ghahremani Jamshid Hadjati |
spellingShingle |
Samaneh Arab Nasim Kheshtchin Maryam Ajami Mahbubeh Ashurpoor Aida Safvati Afshin Namdar Reza Mirzaei Neda Mousavi Niri Farhad Jadidi-Niaragh Mohammad Hossein Ghahremani Jamshid Hadjati Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor Tumor Biology |
author_facet |
Samaneh Arab Nasim Kheshtchin Maryam Ajami Mahbubeh Ashurpoor Aida Safvati Afshin Namdar Reza Mirzaei Neda Mousavi Niri Farhad Jadidi-Niaragh Mohammad Hossein Ghahremani Jamshid Hadjati |
author_sort |
Samaneh Arab |
title |
Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor |
title_short |
Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor |
title_full |
Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor |
title_fullStr |
Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor |
title_full_unstemmed |
Increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor |
title_sort |
increased efficacy of a dendritic cell–based therapeutic cancer vaccine with adenosine receptor antagonist and cd73 inhibitor |
publisher |
IOS Press |
series |
Tumor Biology |
issn |
1423-0380 |
publishDate |
2017-03-01 |
description |
Dendritic cells are important in initiating immune responses; therefore, a range of dendritic cell–based approaches have been established to induce immune response against cancer cells. However, the presence of immunosuppressive mediators such as adenosine in the tumor microenvironment reduces the efficacy of dendritic cell–based cancer immunotherapy. In this study, we investigated whether blockade of the A2A adenosine receptor with a selective antagonist and a CD73 inhibitor may increase the efficacy of a dendritic cell–based cancer vaccine. According to the findings, this therapeutic combination reduced tumor growth, prolonged survival of tumor-bearing mice, and enhanced specific antitumor immune responses. Thus, we suggest that targeting cancer-derived adenosine improves the outcomes of dendritic cell–based cancer immunotherapy. |
url |
https://doi.org/10.1177/1010428317695021 |
work_keys_str_mv |
AT samaneharab increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT nasimkheshtchin increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT maryamajami increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT mahbubehashurpoor increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT aidasafvati increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT afshinnamdar increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT rezamirzaei increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT nedamousaviniri increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT farhadjadidiniaragh increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT mohammadhosseinghahremani increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor AT jamshidhadjati increasedefficacyofadendriticcellbasedtherapeuticcancervaccinewithadenosinereceptorantagonistandcd73inhibitor |
_version_ |
1721487227199946752 |